Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vamotinib - Fusion Pharma

Next Previous
Drug Profile

Vamotinib - Fusion Pharma

Alternative Names: PF-114; PF-114 mesylate

Latest Information Update: 18 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fusion Pharma
  • Class Antineoplastics; Benzamides; Piperazines; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Apoptosis stimulants; Bcr-Abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic myeloid leukaemia

Most Recent Events

  • 18 Feb 2026 Phase-III clinical trials in Chronic myeloid leukaemia (Second-line therapy or greater) is underway in Russia, India, Kazakhstan, Pakistan (PO)(CTRI/2022/06/043337)(700390584)
  • 06 Dec 2025 Efficacy and adverse events data from a phase III trial in Chronic myeloid leukaemia presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 12 Sep 2022 Phase-III clinical trials in Chronic myeloid leukaemia (Second-line therapy or greater) in Russia, India, Kazakhstan, Pakistan (PO)(CTRI/2022/06/043337)(700390584)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top